Loading…
Employees: 696
Size Eiken Chemical (4549.T) is a Japan Health Care company (Medical Specialties) with a market value of $454M, the 1127th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,173 on 6 Nov 2026.
Performance Over six months the shares fell 29.4%, against -13.4% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median -0.6%); the operating margin is 6.5% (peer median 3.7%).
Valuation It trades at 23.6× forward earnings against a peer median of 21.6× (5th most expensive of 10).
Capital Return on invested capital runs 1.4 points below its cost of capital (6.5% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥42.9B | ¥41.9B | ¥40.5B | ¥40.1B | ¥43.3B |
| Revenue growth | — | +3% | +1% | -7% | — |
| Gross profit | ¥17.9B | ¥16.2B | ¥16.5B | ¥16.7B | ¥20.5B |
| EBITDA | n/a | ¥5.46B | ¥5.55B | ¥5.71B | ¥9.58B |
| Net income | ¥1.85B | ¥3.71B | ¥2.23B | ¥2.63B | ¥5.74B |
| Free cash flow | n/a | -¥1.81B | ¥812M | ¥1.77B | ¥4.35B |
| Capital expenditure | n/a | ¥5.86B | ¥5.38B | ¥2.15B | ¥3.29B |
| Total debt | ¥5.80B | ¥7.29B | ¥4.47B | ¥4.33B | ¥4.31B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4549.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | -7.1% | 11th highest of 21 |
| 6-month return | -29.4% | -13.4% | 5th lowest of 21 |
| Distance from 52-week high | -37.9% | -36.9% | 10th lowest of 21 |
| Revenue growth (TTM) | +3.9% | -0.6% | 8th highest of 21 |
| Operating margin | 6.5% | 3.7% | 9th highest of 21 |
| Forward P/E | 23.6× | 21.6× | 5th most expensive of 10 |
| ROIC minus cost of capital | -1.4 pp | -4.5 pp | 7th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 27.4× | 34.3% | +18.8% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 21.6× | 11.8% | +5.6% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | n/a | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | n/a | n/a | n/a |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 9.0× | n/a | n/a |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | n/a | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | n/a | n/a | n/a |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |